Neoleukin Therapeutics

Neoleukin Therapeutics

  • Founded: 2018
  • Location: Seattle, WA
  • Employee range: 50 - 200
  • Clinical stage: RD/Clin0
  • Therapy area: Oncology
  • Drug types: ONC, IMM, ALL
  • Lead product: NL-201
  • Product link:
  • Funding: $76.2M stock Jul 2020

job board

Short description:


Drug notes:

Undisclosed programs RD oncology, autoimmune diseases, allergies

Long description:

Neoleukin Therapeutics is developing novel interleukin-2 (IL-2) therapies to fight cancer. The company's unique science is based on its proprietary IL-2 activation platform, which is designed to overcome the key challenges of IL-2 therapy, including (1) Side effects: IL-2 can cause severe side effects, including fever, fatigue, and organ toxicity. Neoleukin's IL-2 activation platform is designed to minimize these side effects by selectively activating IL-2 in the tumor microenvironment. (2) Limited efficacy: IL-2 has shown limited efficacy in the treatment of solid tumors. Neoleukin's IL-2 activation platform is designed to enhance the efficacy of IL-2 by activating it in the presence of tumor cells.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy